Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Yamamoto, N."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 34
Tytuł:
Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.
Autorzy:
Miwa S; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Yamamoto N; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Hayashi K; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Takeuchi A; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Igarashi K; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Tsuchiya H; Department of Orthopedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jan 20; Vol. 23 (3). Date of Electronic Publication: 2022 Jan 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Mutation*
Antineoplastic Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Chondrosarcoma/*drug therapy
Collagen Type II/*antagonists & inhibitors
Isocitrate Dehydrogenase/*antagonists & inhibitors
Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/genetics ; Bone Neoplasms/metabolism ; Bone Neoplasms/pathology ; Chondrosarcoma/metabolism ; Chondrosarcoma/pathology ; Collagen Type II/genetics ; Humans ; Isocitrate Dehydrogenase/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study.
Autorzy:
Doi T; National Cancer Center Hospital East, Chiba, Japan.
Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Naito Y; National Cancer Center Hospital East, Chiba, Japan.
Kuboki Y; National Cancer Center Hospital East, Chiba, Japan.
Koyama T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Piao Y; Eli Lilly Japan K.K, Kobe, Japan.
Tsujimoto N; Eli Lilly Japan K.K, Kobe, Japan.
Asou H; Eli Lilly Japan K.K, Kobe, Japan.
Inoue K; Eli Lilly Japan K.K, Kobe, Japan.
Kondo S; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Oct; Vol. 10 (19), pp. 6579-6589. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Indazoles/*therapeutic use
Neoplasms/*drug therapy
Niacinamide/*analogs & derivatives
Adult ; Aged ; Antineoplastic Agents/pharmacology ; Female ; Humans ; Indazoles/pharmacology ; Japan ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasms/mortality ; Niacinamide/pharmacology ; Niacinamide/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
Autorzy:
Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-cho Suntou-gun, Shizuoka, 411-8777, Japan. .
Yamaguchi H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo Nagaizumi-cho Suntou-gun, Shizuoka, 411-8777, Japan.
Fukuda M; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences and Clinical Oncology Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Takeshita M; Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, Fukuoka, 802-0077, Japan.
Suetsugu T; Department of Respiratory Medicine, Sendai Medical Association Hospital, 4107-7 Nagatoshi-cho, Satsumasendai, Kagoshima, 895-0005, Japan.
Kirita K; Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Ebi N; Department of Respiratory Medicine, Iizuka Hospital, 3-83 Yoshiomachi, Iizuka, Fukuoka, 820-8505, Japan.
Hataji O; Department of Respiratory Medicine, Matsusaka Municipal Hospital Respiratory Center, 1550 Tonomachi, Matsusaka, Mie, 515-8544, Japan.
Miura S; Department of Internal Medicine, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, Niigata, 951-8566, Japan.
Chibana K; Department of Respiratory Medicine, National Hospital Organization, Okinawa National Hospital, 3-20-14 Ganeko, Ginowan, Okinawa, 901-2214, Japan.
Okamoto I; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yoshimura K; Department of Biostatistics, Innovative Clinical Research Center, Kanazawa University Hospital, Takara-machi, Kanazawa, Ishikawa, 920-8641, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Sugio K; Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu, Oita, 879-5593, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 May 01; Vol. 20 (1), pp. 370. Date of Electronic Publication: 2020 May 01.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Acrylamides*/therapeutic use
Aniline Compounds*/therapeutic use
Antineoplastic Agents*/therapeutic use
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Central Nervous System Neoplasms*/drug therapy
Central Nervous System Neoplasms*/genetics
Central Nervous System Neoplasms*/secondary
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; ErbB Receptors/genetics ; Follow-Up Studies ; Mutation ; Prognosis ; Survival Rate ; Clinical Trials, Phase II as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo.
Autorzy:
Abe K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Yamamoto N; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Hayashi K; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Takeuchi A; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. a_.
Tsuchiya H; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Jul 15; Vol. 19 (1), pp. 689. Date of Electronic Publication: 2019 Jul 15.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Therapy, Combination*
Antineoplastic Agents/*therapeutic use
Bone Neoplasms/*drug therapy
Caffeine/*therapeutic use
Central Nervous System Stimulants/*therapeutic use
Cisplatin/*therapeutic use
Citrates/*therapeutic use
Fibrosarcoma/*drug therapy
Osteosarcoma/*drug therapy
Animals ; Antineoplastic Agents/administration & dosage ; Apoptosis/drug effects ; Caffeine/administration & dosage ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Central Nervous System Stimulants/administration & dosage ; Cisplatin/administration & dosage ; Citrates/administration & dosage ; Drug Synergism ; Female ; Humans ; Membrane Potential, Mitochondrial/drug effects ; Mice ; Mice, Nude ; Treatment Outcome ; Tumor Burden ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
Autorzy:
Takeuchi A; Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Nomura A; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Yamamoto N; Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Hayashi K; Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Igarashi K; Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Tandai S; Department of Orthopaedic Surgery, Asahikawa Medical University, 2-1E Midorigaoka, Asahikawa, Hokkaido, 078-8510, Japan.
Kawai A; Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Matsumine A; Department of Orthopaedics and Rehabilitation Medicine, Unit of Surgery, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, 910-1104, Japan.
Miwa S; Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Nishida Y; Department of Orthopaedic Surgery, Nagoya University School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-8550, Japan.
Nakamura T; Department of Orthopedic Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Terauchi R; Department of Orthopaedic Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho Hirokoji-agaru Kawaramachi-dori Kamigyo-ku, Kyoto, 602-8566, Japan.
Hoshi M; Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-Machi, Abeno-ku, Osaka, 545-8585, Japan.
Kunisada T; Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Endo M; Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Yoshimura K; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Murayama T; Innovative Clinical Research Center (iCREK), Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, 920-8641, Japan.
Tsuchiya H; Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, 13-1 Takara-machi, Kanazawa, 920-8641, Japan. .
Pokaż więcej
Źródło:
BMC musculoskeletal disorders [BMC Musculoskelet Disord] 2019 Feb 09; Vol. 20 (1), pp. 68. Date of Electronic Publication: 2019 Feb 09.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Benzopyrans/*therapeutic use
Giant Cell Tumor of Tendon Sheath/*drug therapy
Propionates/*therapeutic use
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Benzopyrans/adverse effects ; Clinical Trials, Phase II as Topic ; Disease Progression ; Double-Blind Method ; Female ; Giant Cell Tumor of Tendon Sheath/diagnostic imaging ; Giant Cell Tumor of Tendon Sheath/metabolism ; Giant Cell Tumor of Tendon Sheath/pathology ; Humans ; Japan ; Male ; Middle Aged ; Multicenter Studies as Topic ; PPAR gamma/agonists ; PPAR gamma/metabolism ; Progression-Free Survival ; Propionates/adverse effects ; Randomized Controlled Trials as Topic ; Time Factors ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
Autorzy:
Naito T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. .
Okayama T; Division of Rehabilitation Medicine, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Aoyama T; Division of Nutrition, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Ohashi T; Division of Rehabilitation Medicine, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Division of Physical Medicine and Rehabilitation, Shizuoka General Hospital, 4-27-1 Kita Ando Aoi-ku, Shizuoka, 420-8527, Japan.
Masuda Y; Division of Rehabilitation Medicine, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Kimura M; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Tosei-ku, Osaka, 537-8511, Japan.
Shiozaki H; Division of Nutrition, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Taira T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Imai H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Division of Respiratory Medicine, Gunma Prefectural Cancer Center, 617-1 Takabayashi-nishi-machi, Ohta-shi, Gunma, 373-8550, Japan.
Oyakawa T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Division of Cardiology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Ishii T; Division of Rehabilitation Medicine, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Nakashima K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Endo M; Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Omae K; Clinical Research Center, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Mori K; Clinical Research Center, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Yamamoto N; Third Department of Internal Medicine, Wakayama Medical University, 811-1, Kimiidera, Wakayama, 641-8509, Japan.
Tanuma A; Division of Rehabilitation Medicine, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2017 Nov 28; Vol. 17 (1), pp. 800. Date of Electronic Publication: 2017 Nov 28.
Typ publikacji:
Clinical Trial; Journal Article; Observational Study
MeSH Terms:
Activities of Daily Living/*psychology
Antineoplastic Agents/*adverse effects
Cachexia/*psychology
Carcinoma, Non-Small-Cell Lung/*drug therapy
Length of Stay/*economics
Lung Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Agents/therapeutic use ; Cachexia/chemically induced ; Carcinoma, Non-Small-Cell Lung/economics ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/psychology ; Disease-Free Survival ; Female ; Humans ; Longitudinal Studies ; Lung Neoplasms/economics ; Lung Neoplasms/pathology ; Lung Neoplasms/psychology ; Male ; Neoplasm Staging ; Prospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Autorzy:
Ko R; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kenmotsu H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan. .
Serizawa M; Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Koh Y; Division of Drug Discovery and Development, Shizuoka Cancer Center Research Institute, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Wakuda K; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Ono A; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Taira T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Naito T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Isaka M; Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Endo M; Division of Diagnostic Radiology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Nakajima T; Division of Diagnostic Pathology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Ohde Y; Division of Thoracic Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Yamamoto N; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.; Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Takahashi K; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2016 Nov 08; Vol. 16 (1), pp. 864. Date of Electronic Publication: 2016 Nov 08.
Typ publikacji:
Journal Article
MeSH Terms:
Mutation*
Antineoplastic Agents/*pharmacology
Carcinoma, Non-Small-Cell Lung/*genetics
Drug Resistance, Neoplasm/*genetics
ErbB Receptors/*genetics
Lung Neoplasms/*genetics
Protein Kinase Inhibitors/*pharmacology
Adult ; Aged ; Aged, 80 and over ; Alleles ; Amino Acid Substitution ; Biopsy ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Codon ; DNA Mutational Analysis ; Female ; Genotype ; Humans ; Japan ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Male ; Middle Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Simultaneous optimization of limited sampling points for pharmacokinetic analysis of amrubicin and amrubicinol in cancer patients.
Autorzy:
Makino Y; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.; Division of Pharmacokinetics/Pharmacodynamics, Department of Pharmacotherapy, School of Pharmacy, Showa University, Tokyo, Japan.
Watanabe M; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.; Division of Pharmacokinetics/Pharmacodynamics, Department of Pharmacotherapy, School of Pharmacy, Showa University, Tokyo, Japan.
Makihara RA; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Nokihara H; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yamamoto N; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Sugiyama E; Division of Pharmacokinetics/Pharmacodynamics, Department of Pharmacotherapy, School of Pharmacy, Showa University, Tokyo, Japan.
Sato H; Division of Pharmacokinetics/Pharmacodynamics, Department of Pharmacotherapy, School of Pharmacy, Showa University, Tokyo, Japan.
Hayashi Y; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło:
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2016 Sep; Vol. 12 (3), pp. 259-64. Date of Electronic Publication: 2016 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Anthracyclines/*pharmacokinetics
Antineoplastic Agents/*pharmacokinetics
Lung Neoplasms/*drug therapy
Aged ; Area Under Curve ; Female ; Humans ; Lung Neoplasms/metabolism ; Male ; Middle Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Autorzy:
Harima H; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Kaino S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan. .
Takami T; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Shinoda S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Matsumoto T; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.; Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Fujisawa K; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Yamamoto N; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Yamasaki T; Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Sakaida I; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2016 Aug 31; Vol. 16, pp. 702. Date of Electronic Publication: 2016 Aug 31.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Apoptosis/*drug effects
Benzoates/*pharmacology
Cell Proliferation/*drug effects
Pancreatic Neoplasms/*pathology
Triazoles/*pharmacology
Administration, Oral ; Animals ; Cell Cycle/drug effects ; Cell Line, Tumor ; Deferasirox ; Flow Cytometry ; Humans ; Immunohistochemistry ; Iron Chelating Agents/pharmacology ; Mice ; Mice, Nude ; Oligonucleotide Array Sequence Analysis ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Autorzy:
Yasukawa M; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Fujihara H; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .; Department of Oral Hygiene, Tsurumi Junior College, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Fujimori H; Division of Chemotherapy and Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. .; Department of Frontier Life Science, Graduate School of Biochemical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan. .
Kawaguchi K; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Yamada H; Division of Maxillofacial Surgery, Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University 19-1 Uchimaru, Morioka Iwate 020-8050, Japan. .
Nakayama R; Department of Pathology, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Yamamoto N; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. yamamoto.
Kishi Y; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Hamada Y; Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan. .
Masutani M; Division of Chemotherapy and Translational Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. .; Department of Frontier Life Science, Graduate School of Biochemical Science, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan. .
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2016 Feb 24; Vol. 17 (3), pp. 272. Date of Electronic Publication: 2016 Feb 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Synergism*
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Squamous Cell/*drug therapy
Cisplatin/*therapeutic use
Mouth Neoplasms/*drug therapy
Phthalazines/*therapeutic use
Piperazines/*therapeutic use
Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cell Line, Tumor ; Cisplatin/administration & dosage ; Cisplatin/pharmacology ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Phthalazines/administration & dosage ; Phthalazines/pharmacology ; Piperazines/administration & dosage ; Piperazines/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma.
Autorzy:
Tamura Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .; Division of Internal Medicine, Osaka Medical College Hospital, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan. .
Fujiwara Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. fu_ji_@yahoo.co.jp.; Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. fu_ji_@yahoo.co.jp.
Yamamoto N; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .; Department of Experimental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Nokihara H; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Kanda S; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Kubo E; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Kitahara S; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Tsuruoka K; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Tsuta K; Department of Pathology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, 104-0045, Japan. .
Pokaż więcej
Źródło:
BMC research notes [BMC Res Notes] 2015 Dec 18; Vol. 8, pp. 800. Date of Electronic Publication: 2015 Dec 18.
Typ publikacji:
Journal Article
MeSH Terms:
Genes, erbB-1*
Outcome Assessment, Health Care*
Antineoplastic Agents/*pharmacology
Carcinoma/*drug therapy
Lung Neoplasms/*drug therapy
Molecular Targeted Therapy/*methods
Protein-Tyrosine Kinases/*antagonists & inhibitors
Adult ; Aged ; Carcinoma/genetics ; Carcinoma/pathology ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Emerging ethnic differences in lung cancer therapy.
Autorzy:
Sekine I; Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan. />Yamamoto N
Nishio K
Saijo N
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2008 Dec 02; Vol. 99 (11), pp. 1757-62. Date of Electronic Publication: 2008 Nov 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Lung Neoplasms/*drug therapy
Lung Neoplasms/*ethnology
Clinical Trials as Topic ; Humans ; Lung Neoplasms/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
Autorzy:
Nakagawa K; Kinki University School of Medicine, Osakasayama, 589-8511, Japan. />Kudoh S
Matsui K
Negoro S
Yamamoto N
Latz JE
Adachi S
Fukuoka M
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2006 Sep 18; Vol. 95 (6), pp. 677-82. Date of Electronic Publication: 2006 Aug 29.
Typ publikacji:
Clinical Trial, Phase I; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Folic Acid/*administration & dosage
Glutamates/*administration & dosage
Guanine/*analogs & derivatives
Neoplasms/*drug therapy
Vitamin B 12/*administration & dosage
Adult ; Aged ; Alanine Transaminase/blood ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Glutamates/adverse effects ; Glutamates/pharmacokinetics ; Guanine/administration & dosage ; Guanine/adverse effects ; Guanine/pharmacokinetics ; Humans ; Infusions, Intravenous ; Japan ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neutropenia/chemically induced ; Pemetrexed ; Safety ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Cisplatin-induced germ cell apoptosis in mouse testes.
Autorzy:
Zhang X; Department of Urology, Kagawa Medical University, Japan. />Yamamoto N
Soramoto S
Takenaka I
Pokaż więcej
Źródło:
Archives of andrology [Arch Androl] 2001 Jan-Feb; Vol. 46 (1), pp. 43-9.
Typ publikacji:
Journal Article
MeSH Terms:
Apoptosis*
Antineoplastic Agents/*toxicity
Cisplatin/*toxicity
Spermatozoa/*drug effects
Testis/*drug effects
Animals ; In Situ Nick-End Labeling ; Male ; Mice ; Mice, Inbred BALB C
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Coronary vasospasm after interferon administration.
Autorzy:
Yamamoto N; Department of Urology, Gifu University School of Medicine, Japan.
Nishigaki K
Ban Y
Kawada Y
Pokaż więcej
Źródło:
British journal of urology [Br J Urol] 1998 Jun; Vol. 81 (6), pp. 916-7.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Antineoplastic Agents/*adverse effects
Coronary Vasospasm/*etiology
Interferon-gamma/*adverse effects
Aged ; Carcinoma, Renal Cell/drug therapy ; Humans ; Kidney Neoplasms/drug therapy ; Male
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
Autorzy:
Ohyanagi, F.
Yamamoto, N.
Horiike, A.
Harada, H.
Kozuka, T.
Murakami, H.
Gomi, K.
Takahashi, T.
Morota, M.
Nishimura, T.
Endo, M.
Nakamura, Y.
Tsuya, A.
Horai, T.
Nishio, M.
Pokaż więcej
Źródło:
British Journal of Cancer. 7/21/2009, Vol. 101 Issue 2, p225-231. 7p. 3 Charts, 2 Graphs.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803).
Autorzy:
Yamamoto, N.
Fukuoka, M.
Negoro, S.I.
Nakagawa, K.
Saito, H.
Matsui, K.
Kawahara, M.
Senba, H.
Takada, Y.
Kudoh, S.
Nakano, T.
Katakami, N.
Sugiura, T.
Hoso, T.
Ariyoshi, Y.
Pokaż więcej
Źródło:
British Journal of Cancer. 1/12/2004, Vol. 90 Issue 1, p87-92. 6p.
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.
Autorzy:
Inaguma, Y
Akahori, Y
Murayama, Y
Shiraishi, K
Tsuzuki-Iba, S
Endoh, A
Tsujikawa, J
Demachi-Okamura, A
Hiramatsu, K
Saji, H
Yamamoto, Y
Yamamoto, N
Nishimura, Y
Takahashi, T
Kuzushima, K
Emi, N
Akatsuka, Y
Pokaż więcej
Temat:
T cell receptors
ANTIGEN receptors
CHIMERIC proteins
MINOR histocompatibility antigens
GENETIC transformation
ANTINEOPLASTIC agents
IMMUNIZATION
Źródło:
Gene Therapy; Jun2014, Vol. 21 Issue 6, p575-584, 10p
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Autorzy:
Murakami, H.
Kurata, T.
Onozawa, Y.
Watanabe, J.
Ono, A.
Takahashi, T.
Yamamoto, N.
Fujisaka, Y.
Kiyota, H.
Hayashi, H.
Tanaka, K.
Nakagawa, K.
Kuroda, S.
Pokaż więcej
Temat:
PHARMACOKINETICS
INTRAVENOUS therapy
JAPANESE people
ANTINEOPLASTIC agents
LYMPHOPENIA
HYPERTENSION
DIARRHEA
DISEASES
Źródło:
Cancer Chemotherapy & Pharmacology; Mar2014, Vol. 73 Issue 3, p623-630, 8p
Czasopismo naukowe
Szczegóły
Tytuł:
Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
Autorzy:
Nishio, M
Horai, T
Horiike, A
Nokihara, H
Yamamoto, N
Takahashi, T
Murakami, H
Koizumi, F
Nishio, K
Yusa, W
Koyama, N
Tamura, T
Pokaż więcej
Temat:
LUNG cancer
CARBOPLATIN
PACLITAXEL
PROTEIN-tyrosine kinases
ANTINEOPLASTIC agents
RESPONSE rates
Źródło:
British Journal of Cancer; 8/6/2013, Vol. 109 Issue 3, p538-544, 7p, 5 Charts, 1 Graph
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 34

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies